Promising combo for prostate cancer falls short in early trial
NCT ID NCT01885949
First seen Mar 05, 2026 · Last updated May 11, 2026 · Updated 10 times
Summary
This study tested a combination of two drugs—enzalutamide (already approved for prostate cancer) and tivozanib (an experimental drug that cuts off a tumor's blood supply)—in men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to see if the combo could delay cancer growth longer than enzalutamide alone. Only 5 men enrolled before the study was ended early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.